Long arginine 3-IGF-1, abbreviated as IGF-1 LR3 or LR3-IGF-1, is a synthetic protein and lengthened analogue of human insulin-like growth factor 1 (IGF-1).[1][2] It differs from native IGF-1 in that it possesses an arginine instead of a glutamic acid at the third position in its amino acid sequence (arginine 3), and also has an additional 13 amino acids at its N-terminus (MFPAMPLLSLFVN) (long), for a total of 83 amino acids (relative to the 70 of IGF-1).[2] The consequences of these modifications are that IGF-1 LR3 retains the pharmacological activity of IGF-1 as an agonist of the IGF-1 receptor, has very low affinity for the insulin-like growth factor-binding proteins (IGFBPs), and has improved metabolic stability.[1][2] As a result, it is approximately three times more potent than IGF-1,[3] and possesses a significantly longer half-life of about 2030 hours (relative to IGF-1s half-life of about 1215 hours).[4] IGF-1 LR3 Peptide is under active investigation in a number of cell culture and animal models

Through firsthand insights from cornea specialists, well take a closer look at how treatment strategies are developing, the role of ML-AMT in complex cases, and what innovations may shape the future of care
Clinical studies have demonstrated substantial weight reduction in participants using Tirzepatide, which opens up exciting possibilities for its application as an anti-obesity treatment
The PRL-R is expressed in a wide array of tissues, and a growing number of biological processes continue to be attributed to prolactin
Because B12 is water-soluble, it is considered safe to take in high-dose supplements
It was at the Wartburg that Luther began to make his famous translation of the New Testament